Fraunhofer Institute for Cell Therapy and Immunology, Department Therapy Validation, Leipzig, Germany.
AnaPath GmbH, Liestal, Switzerland.
Sci Rep. 2017 Oct 27;7(1):14214. doi: 10.1038/s41598-017-13985-x.
Inflammatory bowel diseases are multifactorial disorders of the gastrointestinal tract with rising incidence worldwide. Current standard therapies are only partially effective and often show severe adverse effects. Thus, novel, more efficient and well-tolerated therapeutic options are urgently needed. We have studied the therapeutic potential of a phytopharmaceutical combining sage and bitter apple (SBA) in the mouse model of chronic dextran sulfate sodium (DSS) colitis. SBA represents a traditional medicine against diarrhea and was shown to exhibit anti-inflammatory effects in vitro. In the chronic DSS colitis model SBA treatment significantly reduced clinical symptoms in a dose-dependent manner. The positive therapeutic effect of SBA was characterized by a decreased histopathological score indicating tissue healing. Moreover, the number of neutrophils as well as the expression of the neutrophil-recruiting chemokine CXCL-1/KC in the colon tissue was significantly reduced, whereas the recruitment of macrophages was induced. Also, the expression of inflammatory markers was significantly suppressed, while the expression of the anti-inflammatory cytokine interleukin-10 was induced in colon tissue following treatment with SBA. Phytopharmaceuticals are increasingly recognized as potential therapeutics in IBD. Thus, based on the results from this study, SBA can be considered as an alternative or supplementary option for IBD therapy.
炎症性肠病是一种多因素的胃肠道疾病，全球发病率呈上升趋势。目前的标准治疗方法仅部分有效，且常表现出严重的不良反应。因此，迫切需要新的、更有效且耐受良好的治疗选择。我们研究了一种结合鼠尾草和苦苹果（SBA）的植物药在慢性葡聚糖硫酸钠（DSS）结肠炎小鼠模型中的治疗潜力。SBA 是一种治疗腹泻的传统药物，体外研究表明其具有抗炎作用。在慢性 DSS 结肠炎模型中，SBA 治疗可显著减轻临床症状，且呈剂量依赖性。SBA 的治疗效果为组织修复的组织学评分降低。此外，结肠组织中中性粒细胞数量以及中性粒细胞募集趋化因子 CXCL-1/KC 的表达显著减少，而巨噬细胞的募集增加。SBA 处理后，结肠组织中炎症标志物的表达显著受到抑制，而抗炎细胞因子白细胞介素-10 的表达增加。植物药被越来越多地认为是 IBD 治疗的潜在药物。因此，基于本研究的结果，SBA 可被视为 IBD 治疗的一种替代或补充选择。
